B.C.-based psychedelic drug Clearmind Medicine has filed to raise up to $14 million through a U.S. initial public offering.
Earlier this month, the company announced that Dr. John H. Krystal, a world-leading expert on alcoholism and depression, had joined Clearmind’s scientific advisory board.
Chair of the Psychiatry Department at Yale University’s School of Medicine, Krystal is best known for leading the discovery of the rapid antidepressant effects of ketamine, according to a press release.
“We are truly honoured to add Dr. Krystal, one of the world’s most recognized experts in alcoholism, to our Scientific Advisory Board,” Dr. Adi Zuloff-Shani, Clearmind’s CEO, said in a statement.
“We believe that the scientists on our Scientific Advisory Board, working closely with us to challenge, validate and guide our scientific agenda for developing breakthrough therapies that improve human mental health at scale, increase access to care, reduce
Read full article on The Growth Op